Recent advances in the management of chemotherapy-induced neutropenia: biosimilar granulocyte colony-stimulating factor use in Italy

• Published in: Future oncology (London, England) Vol. 16; no. 14; pp. 891 - 897
• Main Authors: Danova, Marco, Pronzato, Paolo, Ingrasciotta, Ylenia, Antonuzzo, Andrea, Trama, Ugo, Tondini, Carlo, Bernardi, Francesca Futura
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.05.2020
• Subjects: Biological products; biosimilar; Biosimilar Pharmaceuticals - administration & dosage; Biosimilar Pharmaceuticals - adverse effects; Biosimilar Pharmaceuticals - therapeutic use; Breast cancer; Cancer therapies; Chemotherapy; Chemotherapy-Induced Febrile Neutropenia - blood; Chemotherapy-Induced Febrile Neutropenia - diagnosis; Chemotherapy-Induced Febrile Neutropenia - etiology; Chemotherapy-Induced Febrile Neutropenia - therapy; Clinical trials; Cost reduction; Disease Management; Drug dosages; febrile neutropenia; filgrastim; G-CSF; Granulocyte Colony-Stimulating Factor - administration & dosage; Granulocyte Colony-Stimulating Factor - adverse effects; Granulocyte Colony-Stimulating Factor - therapeutic use; Humans; Italy; Leukocyte Count; Meta-analysis; Mortality; Neutropenia; Neutrophils; Outcome Assessment, Health Care; Patients; pegfilgrastim; Pharmacodynamics; Pharmacokinetics; Prevention; Randomized Controlled Trials as Topic; Regulation; Italy; United States > US; filgrastim; pegfilgrastim; febrile neutropenia; G-CSF; biosimilar
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2020-0167

During the National Congress of the Italian Association of Medical Oncology, which was held in Rome, Italy, October 2019, experts met to discuss advantages of febrile neutropenia prevention based on biosimilar G-CSF. This issue is of paramount importance in oncology as recent biological products may be of great benefit, provided that costs are sustainable.